Understanding the salinity issue of coal mine spoils in the context of salt cycle

Coal mine spoils (CMSs), the solid wastes originated from the rock formations and soil cover overlying or interbedded with coal seams, are a worldwide environmental management challenge. Previous studies have shown that salinity is of most concern among the CMSs' environmental impacts, especially in Australia. With increasing concerns from both the governments and communities, there is a real need for the coal mining industry to understand the source, dynamics and management options of CMS salinity. We reviewed the general properties of CMSs from coal mine sites worldwide and the current understanding of the CMS salinity, which are in a limited number of available published reports. Properties (e.g., pH, electrical conductivity and hydraulic conductivity) of studied CMSs varied largely due to its complex lithological origination. A conceptual model was proposed to illustrate the origin, dispersion paths and transformations dynamics of salts in spoils, taking the scenario of a coal mine in Australia as an example. The major factors governing the salt dynamics in CMSs are summarized as mineral weatherability and salt leachability of the spoils. Management of CMS salinity is still a vague area awaiting more extensive studies. Three topics related to the management were explored in the review, which are pre-mining planning, spatial variability of spoil properties and remediation including electrokinetics and phytoremediation. Particularly, based on the geological classification of CMSs and the leachate chemistry of spoils of various sources, a clear relationship between salinity and geounits was established. This association has a potential application in pre-mining planning for the management of salinity from coal mine spoils

Understanding the salinity issue of coal mine spoils in the context of salt cycle

Coal mine spoils (CMSs), the solid wastes originated from the rock formations and soil cover overlying or interbedded with coal seams, are a worldwide environmental management challenge. Previous studies have shown that salinity is of most concern among the CMSs' environmental impacts, especially in Australia. With increasing concerns from both the governments and communities, there is a real need for the coal mining industry to understand the source, dynamics and management options of CMS salinity. We reviewed the general properties of CMSs from coal mine sites worldwide and the current understanding of the CMS salinity, which are in a limited number of available published reports. Properties (e.g., pH, electrical conductivity and hydraulic conductivity) of studied CMSs varied largely due to its complex lithological origination. A conceptual model was proposed to illustrate the origin, dispersion paths and transformations dynamics of salts in spoils, taking the scenario of a coal mine in Australia as an example. The major factors governing the salt dynamics in CMSs are summarized as mineral weatherability and salt leachability of the spoils. Management of CMS salinity is still a vague area awaiting more extensive studies. Three topics related to the management were explored in the review, which are pre-mining planning, spatial variability of spoil properties and remediation including electrokinetics and phytoremediation. Particularly, based on the geological classification of CMSs and the leachate chemistry of spoils of various sources, a clear relationship between salinity and geounits was established. This association has a potential application in pre-mining planning for the management of salinity from coal mine spoils

The Relationship Between Pharmacogenomics and Pharmacokinetics and Its Impact on Drug Choice and Dosing Regimens in Pediatrics

The concept of precision or personalized medicine in pediatrics is still in its infancy, and due to ethical and logistical constraints, it is difficult to conduct clinical studies in pediatric to obtain meaningful correlations between ontogeny and drug disposition. However, as a result of initiatives by the Food and Drug Administration (FDA) aimed toward incentivizing companies for conducting pediatric trials, knowledge on pediatric pharmacogenomics is slowly increasing. The information on pediatric pharmacogenomics is utilized to implement pharmacogenomic testing in pediatrics to allow clinicians to make an informed decision on selection and dosing of drugs in pediatrics. The ontogeny of drug-metabolizing enzymes (DMEs), transporters, and target proteins is the most crucial factor in pediatric pharmacogenomics. Based on in vitro and in vivo studies on the ontogeny of DMEs, various pharmacogenomic tests in pediatrics were evaluated concerning the pharmacokinetics of drugs utilized in pediatric pharmacotherapy. Needing to obtain clinically relevant advantages of incorporating pharmacogenomics in pediatric drug therapy, clinicians must be informed on pharmacogenomic terms by appropriate educational programs. Furthermore, a comprehensive database that can bank all pediatric pharmacogenomic information that can seamlessly collaborate with other international databases must be established

Effect of Kidney Function on Drug Kinetics and Dosing in Neonates, Infants, and Children

Neonates, infants, and children differ from adults in many aspects, not just in age, weight, and body composition. Growth, maturation and environmental factors affect drug kinetics, response and dosing in pediatric patients. Almost 80% of drugs have not been studied in children, and dosing of these drugs is derived from adult doses by adjusting for body weight/size. As developmental and maturational changes are complex processes, such simplified methods may result in subtherapeutic effects or adverse events. Kidney function is impaired during the first 2 years of life as a result of normal growth and development. Reduced kidney function during childhood has an impact not only on renal clearance but also on absorption, distribution, metabolism and nonrenal clearance of drugs. 'Omics'-based technologies, such as proteomics and metabolomics, can be leveraged to uncover novel markers for kidney function during normal development, acute kidney injury, and chronic diseases. Pharmacometric modeling and simulation can be applied to simplify the design of pediatric investigations, characterize the effects of kidney function on drug exposure and response, and fine-tune dosing in pediatric patients, especially in those with impaired kidney function. One case study of amikacin dosing in neonates with reduced kidney function is presented. Collaborative efforts between clinicians and scientists in academia, industry, and regulatory agencies are required to evaluate new renal biomarkers, collect and share prospective pharmacokinetic, genetic and clinical data, build integrated pharmacometric models for key drugs, optimize and standardize dosing strategies, develop bedside decision tools, and enhance labels of drugs utilized in neonates, infants, and children